Cyclophosphamide is used to restrict growth of malicious cells in malignant diseases in adults and children such as malignant lymphomas (Stages III and IV), Hodgkin’s disease, Non-Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and monocytic leukemia, acute lymphoblastic leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, Ewing’s sarcoma, breast cancer.
It is also indicated for the treatment of nephrotic syndrome in children who fail to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. It is not recommended for use in patients with acute infections, bone-marrow aplasia, and urinary tract infections like cystitis, acute urothelial toxicity from cytotoxic chemotherapy or radiation therapy, or urinary outflow obstruction.
Cyclophosphamide: Alkylating agents
Cyclophosphamide works by interfering with the malignant cell growth by cross-linking of cancer cells’ DNA. It also transfers alkyl groups to DNA during the process of cell division, thus preventing the normal synthesis of DNA. Therefore, stopping the growth and multiplication of cancer cells.
Consult your doctor: